CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.

Among over 125,000 patients, 53.6% discontinued their GLP-1 receptor agonist by 1 year, and these rates were significantly ...

Scouted selects products independently. If you purchase something from our posts, we may earn a small commission. Unless you ...

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

A small percentage of patients taking GLP-1 medications have experienced vision problems, but a direct causal link with the ...

Cardinal Health had $210 billion in pharmaceutical and specialty drugs sales in fiscal 2024, up 11% year-over-year, helped in large part by GLP-1 sales. In Q4, segment sales rose 13% to $55 billion, ...

GLP-1 agonists like Ozempic, Trulicity, Mounjaro, Victoza, Wegovy started as a way to treat diabetes but have since become popular for weight loss.

and $17.7 billion for tirzepatide (Mounjaro/Zepbound). The company's pipeline includes promising candidates such as Amycretin, an oral GLP-1/Amylin co-agonist that has shown competitive weight ...

"It is estimated that by 2030, 30 million GLP-1 [receptor agonist] prescriptions will have been dispensed in the U.S. Despite the rarity of NAION, the large number of users of these drugs can ...